DR. PIER CIPRIANI, D.D.S
Dentist in Upper Makefield, PA
License number
Pennsylvania 10312
Category
Dentist
Type
General Practice
Address
Address
638 Yardley Newtown Rd SUITE 2C, Upper Makefield, PA 18940
Phone
(215) 968-0620
(215) 968-0625 (Fax)
(215) 968-0625 (Fax)
Professional information
Dr. Pier Cipriani, Newtown PA - DDS (Doctor of Dental Surgery)
Specialties:
Dentistry
Address:
638 Newtown Yardley Rd STE 2C, Newtown 18940
(215) 968-0620 (Phone), (215) 968-0625 (Fax)
(215) 968-0620 (Phone), (215) 968-0625 (Fax)
Languages:
English
Education:
Medical School
Graduates of Institutions Not Listed As Medical Schools
Graduates of Institutions Not Listed As Medical Schools
Method And Kit For Epithelial Cancer Screening
US Patent:
6417003, Jul 9, 2002
Filed:
Sep 13, 1994
Appl. No.:
07/978670
Inventors:
Pier J. Cipriani - Newtown PA
Assignee:
Zila, Inc. - Phoenix AZ
International Classification:
G01N 3348
US Classification:
436 64, 422 61, 424 97
Abstract:
A method and kit for screening patients for oral epitheleal cancer. The clinician is provided with a kit containing the staining dye test solution in preselected concentration and volume in prepackaged form, to permit the clinician to dispense the solution directly from the package without diluting or reconstituting before application to oral tissue.
Pier Cipriani, Newtown PA
Specialties:
Dentist
Address:
638 Newtown Yardley Rd, Newtown, PA 18940
Method Of In Situ Diagnosis By Spectroscopic Analysis Of Biological Stain Compositions
US Patent:
2005017, Aug 11, 2005
Filed:
Mar 8, 2005
Appl. No.:
11/073845
Inventors:
Mark Malmros - Washington Crossing PA, US
William Collins - San Diego CA, US
Pier Cipriani - Newtown PA, US
William Collins - San Diego CA, US
Pier Cipriani - Newtown PA, US
Assignee:
Azurtec, Inc. - Washington Crossing PA
International Classification:
C12Q001/68, G06F019/00, G01N033/48, G01N033/50
US Classification:
435006000, 435040500, 702019000
Abstract:
A method is disclosed where one or more biological stains are applied to living tissue displaying, or suspected of having cells, or parts of the tissue which are diseased, metaplasic, or otherwise abnormal, including but not limited to lesions which may be thought pre-cancerous or cancerous. The stained tissue is then analyzed, in situ, by reflectance spectroscopy, the results of which are then compared to a digital library of reflectance spectrums of such tissue that have been previously diagnosed by conventional histochemical techniques. The method is further disclosed as a means to monitor the progress of photodynamic therapy using the same biological stains as specific photosensitizers.
Bio-Spectral Imaging System And Methods For Diagnosing Cell Disease State
US Patent:
2003002, Feb 6, 2003
Filed:
Apr 26, 2002
Appl. No.:
10/132278
Inventors:
Mark Malmros - Washington Crossing PA, US
William Collins - San Diego CA, US
Pier Cipriani - Newtown PA, US
Dennis Loreman - Bristol PA, US
William Collins - San Diego CA, US
Pier Cipriani - Newtown PA, US
Dennis Loreman - Bristol PA, US
International Classification:
A61K049/00
US Classification:
424/009600, 514/224800
Abstract:
A bio-spectral imaging system and methods for in situ diagnosis of a disease state in biological tissue or cells of a living organism are provided. In one form, a method includes applying to the tissue or cells in situ a biological stain composition that includes at least one metachromatic dye; performing a spectral analysis to obtain at least one spectrum of the stained tissue or cells; comparing the spectrum with spectra from a library of spectra of similarly stained reference tissue or cells that have been categorized as diseased or non-diseased; and correlating the spectrum to a disease state. The system and methods may be used to diagnose, for example, pre-cancer and/or cancer, as well as diseases caused by various microorganisms. Methods for creating a library of spectra, methods for monitoring the efficiency of photodynamic therapy of diseased biological tissue or cells in vivo, as well as methods for improving the efficiency of photodynamic therapy are also provided.
Method Of In Situ Diagnosis By Spectroscopic Analysis Of Biological Stain Compositions
US Patent:
2002005, May 16, 2002
Filed:
May 5, 1999
Appl. No.:
09/306662
Inventors:
MARK K. MALMROS - WASHINGTON CROSSING PA, US
WILLIAM S. COLLINS - SAN DIEGO CA, US
PIER J. CIPRIANI - NEWTOWN PA, US
WILLIAM S. COLLINS - SAN DIEGO CA, US
PIER J. CIPRIANI - NEWTOWN PA, US
International Classification:
A61B005/00, A61B008/00, A61B010/00, A61K039/395, C07K016/00, C12P021/08
US Classification:
424/130100, 424/155100, 530/388850
Abstract:
A method is disclosed where one or more biological stains are applied to living tissue displaying, or suspected of having cells, or parts of the tissue which are diseased, metaplasic, or otherwise abnormal, including but not limited to lesions which may be thought pre-cancerous or cancerous. The stained tissue is then analyzed, in situ, by reflectance spectroscopy, the results of which are then compared to a digital library of reflectance spectrums of such tissue that have been previously diagnosed by conventional histochemical techniques. The method is further disclosed as a means to monitor the progress of photodynamic therapy using the same biological stains as specific photosensitizers.
Biological Stain Composition, Method Of Preparation And Method Of Use For Delineation Of Epithelial Cancer
US Patent:
5372801, Dec 13, 1994
Filed:
Jun 7, 1993
Appl. No.:
8/067506
Inventors:
Mark K. Malmros - Newton PA
Raymond J. Tucci - Yardley PA
Pier J. Cipriani - Newtown PA
Raymond J. Tucci - Yardley PA
Pier J. Cipriani - Newtown PA
Assignee:
CTM Associates, Inc. - Newtown PA
International Classification:
A61K 3154
US Classification:
424 71
Abstract:
A biological stain composition contains toluidine blue O and a pharmaceutically acceptable oxidizing agent to convert any leuco toluidine blue O to the chromo form. A dry composition for preparing the stain includes the toluidine blue O, the oxidizing agent and an effervescent agent. These compositions are preferably buffered to improve shelf stability and clinical consistency. Compositions for intra-oral application contain a flavoring agent.